sICAM-1
Alternative Names: BIRR 4; sICAM; sICAM-rhinovirus; soluble ICAM-1; tremacamraLatest Information Update: 24 Oct 2021
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Isis Pharmaceuticals
- Class Antivirals; Glycoproteins
- Mechanism of Action Immunomodulators; Virus attachment inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
- Discontinued Diabetes mellitus; Rhinovirus infections
Most Recent Events
- 08 May 2003 Discontinued - Preclinical for Diabetes mellitus in Germany (unspecified route)
- 29 Sep 2000 Discontinued-II for Rhinovirus infections in USA (Intranasal)
- 29 Sep 2000 Discontinued-Preclinical for Rhinovirus infections in Germany (Unknown route)